Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Arizona
-
Goodyear, Arizona, United States, 85338
-
Phoenix, Arizona, United States, 85013
-
Tucson, Arizona, United States, 85724
-
-
California
-
Salinas, California, United States, 93901
-
Whittier, California, United States, 90603
-
-
Colorado
-
Englewood, Colorado, United States, 80113
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
-
New Britain, Connecticut, United States, 6052
-
-
Georgia
-
Augusta, Georgia, United States, 30912
-
-
Illinois
-
Hinsdale, Illinois, United States, 60521
-
Joliet, Illinois, United States, 60435
-
Skokie, Illinois, United States, 60076
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
-
Indianapolis, Indiana, United States, 46202
-
-
Maryland
-
Baltimore, Maryland, United States, 21237
-
Cumberland, Maryland, United States, 21502
-
-
Montana
-
Missoula, Montana, United States, 59802
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
-
-
New York
-
Buffalo, New York, United States, 14263-0001
-
New York, New York, United States, 10021
-
Watertown, New York, United States, 57201
-
-
Ohio
-
Canton, Ohio, United States, 44718
-
Cleveland, Ohio, United States, 44106-5067
-
Columbus, Ohio, United States, 43212
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19124
-
Pittsburgh, Pennsylvania, United States, 15213
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37403
-
-
Utah
-
Salt Lake City, Utah, United States, 84132-0001
-
-
Virginia
-
Annandale, Virginia, United States, 22003
-
-
Washington
-
Tacoma, Washington, United States, 98405
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histologically documented ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma that has recurred > 6 months after platinum-based chemotherapy
- This must be the first recurrence of the epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma
- Are at least two weeks but no more than 3 months after the completion of second-line cytotoxic chemotherapy
- Are currently under observation or being treated with bevacizumab as a second-line maintenance therapy
- Have a valid email address and access to the internet
- Provide voluntary written informed consent
- Speak and read English fluently
Exclusion Criteria:
- Current participation in a blinded clinical trial for ovarian cancer treatment. (Participation in a trial involving only supportive care medicines and/or growth factors is acceptable)
- Another primary diagnosis of cancer in a different site
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Cohort
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in MD Anderson Symptom Inventory-Ovarian Cancer (MDASI-OC) sub-set symptom severity score before and after disease progression
Time Frame: Up to 9 months
|
Up to 9 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
MDASI-OC Symptom Severity Score
Time Frame: Up to 9 months
|
Up to 9 months
|
|
MDASI-OC Symptom Interference Score
Time Frame: By month 9
|
By month 9
|
|
HRQoL scores
Time Frame: Up to 9 months
|
Up to 9 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
Other Study ID Numbers
- ML28066
- 130/070 (Other Identifier: Genentech)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.